TransMedics Group Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TransMedics Group stock.
View analyst ratings for TransMedics Group or view top-rated stocks.

Wall Street analysts have given TransMedics Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TransMedics Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

TransMedics Group saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 1,260,000 shares, an increase of 23.5% from the May 13th total of 1,020,000 shares. Based on an average daily volume of 590,300 shares, the days-to-cover ratio is currently 2.1 days. Currently, 5.1% of the shares of the stock are sold short.
View TransMedics Group's Short Interest.

TransMedics Group is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for TransMedics Group.

TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings data on Tuesday, May, 4th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.01. TransMedics Group had a negative trailing twelve-month return on equity of 26.18% and a negative net margin of 110.54%.
View TransMedics Group's earnings history.

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TMDX stock has increased by 107.9% and is now trading at $28.31.
View which stocks have been most impacted by COVID-19.

5 equities research analysts have issued twelve-month price targets for TransMedics Group's stock. Their forecasts range from $15.00 to $79.00. On average, they expect TransMedics Group's share price to reach $43.60 in the next twelve months. This suggests a possible upside of 54.0% from the stock's current price.
View analysts' price targets for TransMedics Group or view top-rated stocks among Wall Street analysts.

17 employees have rated TransMedics Group CEO Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among TransMedics Group's employees.

Some companies that are related to TransMedics Group include InMode (INMD), Outset Medical (OM), BioLife Solutions (BLFS), Natus Medical (NTUS), ViewRay (VRAY), AxoGen (AXGN), Cutera (CUTR), Semler Scientific (SMLR), Stereotaxis (STXS), Zynex (ZYXI), Edap Tms (EDAP), Second Sight Medical Products (EYES), Movano (MOVE), BioSig Technologies (BSGM) and IRIDEX (IRIX).
View all of TMDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and The Walt Disney (DIS).

(TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

TransMedics Group's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.89%), Credit Suisse AG (5.44%), Sandhill Capital Partners LLC (4.33%), KPCB XIII Associates LLC (3.34%), Bellevue Group AG (2.69%) and Federated Hermes Inc. (2.19%). Company insiders that own TransMedics Group stock include Abrams Capital Management, LP, David Weill, James R Tobin, John F Carey, John F Sullivan, Stephen Gordon, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends for TransMedics Group.

TMDX stock was sold by a variety of institutional investors in the last quarter, including Zimmer Partners LP, Emerald Advisers LLC, Sandhill Capital Partners LLC, Northern Trust Corp, JPMorgan Chase & Co., Taylor Wealth Management Partners, KPCB XIII Associates LLC, and Squarepoint Ops LLC. Company insiders that have sold TransMedics Group company stock in the last year include Abrams Capital Management, LP, James R Tobin, John F Carey, John F Sullivan, Stephen Gordon, Tamer I Khayal, and Waleed H Hassanein.
View insider buying and selling activity for TransMedics Group or view top insider-selling stocks.

TMDX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Federated Hermes Inc., Stephens Inc. AR, Dimensional Fund Advisors LP, Voloridge Investment Management LLC, Bellevue Group AG, Morgan Stanley, and Nuveen Asset Management LLC.
View insider buying and selling activity for TransMedics Group or or view top insider-buying stocks.

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TMDX stock can currently be purchased for approximately $28.31.

TransMedics Group has a market capitalization of $782.04 million and generates $25.64 million in revenue each year. The company earns $-28,750,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

TransMedics Group employs 110 workers across the globe.

The official website for TransMedics Group is www.transmedics.com.

TransMedics Group is headquartered at 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810.

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]